<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-TUKOANU7/deee7d3d-7eb1-44c0-be88-460f560b8025/HTML"><dcterms:extent>37 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-TUKOANU7/02b7419a-ded5-4b07-96bb-85480e46ad81/PDF"><dcterms:extent>324 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-TUKOANU7/1eba67d5-c025-413d-8873-50f8f5bbbda1/TEXT"><dcterms:extent>30 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="1992-2025"><edm:begin xml:lang="en">1992</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:doc-TUKOANU7"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:spr-FNIFVE9S" /><dcterms:issued>2003</dcterms:issued><dc:creator>Budíková, Marie</dc:creator><dc:creator>Horová, Hana</dc:creator><dc:creator>Horová, Ivana</dc:creator><dc:creator>Soumarová, Renata</dc:creator><dc:creator>Šeneklová, Zuzana</dc:creator><dc:format xml:lang="sl">10 strani</dc:format><dc:format xml:lang="sl">številka:2</dc:format><dc:format xml:lang="sl">letnik:37</dc:format><dc:format xml:lang="sl">str. 79-88</dc:format><dc:identifier>ISSN:1318-2099</dc:identifier><dc:identifier>COBISSID:16558297</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-TUKOANU7</dc:identifier><dc:language>en</dc:language><dc:publisher xml:lang="sl">Association of Radiology and Oncology</dc:publisher><dcterms:isPartOf xml:lang="sl">Radiology and oncology (Ljubljana)</dcterms:isPartOf><dc:subject xml:lang="en">breast</dc:subject><dc:subject xml:lang="en">Breast Neoplasms</dc:subject><dc:subject xml:lang="sl">Dojka, novotvorbe</dc:subject><dc:subject xml:lang="sl">dojke</dc:subject><dc:subject xml:lang="sl">kirurško zdravljenje</dc:subject><dc:subject xml:lang="en">Mastectomy</dc:subject><dc:subject xml:lang="sl">Mastektomija</dc:subject><dc:subject xml:lang="en">Neoplasm Recurrence, Local</dc:subject><dc:subject xml:lang="en">Neoplasm Staging</dc:subject><dc:subject xml:lang="sl">Novotvorba, ponovitev lokalna</dc:subject><dc:subject xml:lang="sl">Novotvorba, stadij</dc:subject><dc:subject xml:lang="sl">Preživetje, analiza</dc:subject><dc:subject xml:lang="en">Prognosis</dc:subject><dc:subject xml:lang="sl">Prognoza</dc:subject><dc:subject xml:lang="sl">Radioterapija pomožna</dc:subject><dc:subject xml:lang="en">Radiotherapy</dc:subject><dc:subject xml:lang="en">Radiotherapy, Adjuvant</dc:subject><dc:subject xml:lang="sl">rak (medicina)</dc:subject><dc:subject xml:lang="en">Retrospective Studies</dc:subject><dc:subject xml:lang="sl">Retrospektivne študije</dc:subject><dc:subject xml:lang="en">Surgery</dc:subject><dc:subject xml:lang="en">Survival Analysis</dc:subject><dc:subject xml:lang="en">therapy</dc:subject><dc:subject xml:lang="sl">zdravljenje</dc:subject><dcterms:temporal rdf:resource="1992-2025" /><dc:title xml:lang="sl">Prognostic outcome of local recurrence in breast cancer after conserving surgery and mastectomy|</dc:title><dc:description xml:lang="sl">Background. In our retrospective study we analysed local recurrences in breastcancer patients treated with conserving surgery (CS) followed by adjuvant radiotherapy (RT) or mastectomy (ME) with or without radiotherapy. Weanalysed the impact of local recurrence on overall survival. Patients and methods. Between 1980-1995, 306 patients underwent conserving surgery and 1,193 patients were done mastectomy in Masaryk Memorial Cancer Institute. The patients lost to follow-up were excluded. After all, we analysed 236 patients who underwent conserving surgery (Group A), and 1,121 who underwent mastectomy(Group B). All patients with CS received adjuvant RT of the breast with or without regional lymph nodes. In 982 patients (87,6%) with ME, we performed RT of the chest wall or without regional lymph nodes. Median age at the time of diagnosis was 48.3 years in Group A and 52.1 years in Group B. In Group A, 149 patients (63.1%) had T1 tumour, 86 (36.4%) T2 and 1(0.5%)T3. In 24.2% of patients, axillary node involvement was observed. In Group B, 316 patients (30.4%) had T1 tumour. 607 (58.3%) T2, 76 (7.3%) T3, 33 (3.2%) T4 and9 (0.9%) TX. In 46.2% of these patients, we found axillary node involvement. Invasive ductal carcinoma was histologically proved in 67.4% in Group A and 84% in Group B. Systemic treatment was given to 133 patients (56.4%) from Group A and to 857 patients (76.4%) from Group B. Results. Medianfollow-up was 100.5 months in Group A and 121 months in Group B. In Group A, we registered 22 (9.3%) local recurrences, 5-year local control was 96.2% and median time to local recurrence was 50 months. In Group B, we registered 65 (5.8%) local recurrences; 5-year local control was 96.6%. Five-year local control in patients with T1, T2 tumours was 97.2%. In patientswith adjuvant RT median time to local recurrence was 48.5 months, and in patients without adjuvant RT 51 months. (Abstract truncated at 2000 characters)</dc:description><dc:description xml:lang="sl">Izhodišča. V retrospektivni študiji smo analizirali lokalne ponovitve bolezni pri bolnicah z rakom dojke. Bolnice so bile zdravljenje z ohranitveno kirurgijo (CS), ki ji je sledila adjuvantna radioterapija (RT ali pa so bile zdravljenje z mastektomijo (ME) in nekatere od njih tudi z RT. Ugotavljali smovpliv lokalne ponovitve bolezni na preživetje. Bolniki in metode. Med leti 1980-1995 smo v naši ustanovi zdravili 306 bolnic z ohranitveno kirurgijo in 1193 bolnic z mastektomijo. Izključili smo bolnice, pri katerih nismo uspeli slediti poteka bolezni. Tako smo analizirali 236 bolnic po CS (skupina A) in 1121 bolnic po ME (skupina B). Vsem bolnicam s CS smo obsevali operirano dojko, nekaterim pa tudi regionalne limfne bezgavke. Pri bolnicah z ME pa smo le pri 982 (87,6%) obsevali dojko in nekaterim od njih tudi regionalne bezgavke. Srednja starost v času diagnoze je bila 48,3 let v skupini A in 52,1let v skupini B. V skupini A je imelo 149 bolnic (63,1%) tumor T1, 86 (36,4%) T2 in 1 (0,5%) T3. Pri 24,2% bolnic se je rak razširil v pazdušne bezgavke. V skupini B je imelo 316 (30,4%) bolnic tumor T1, 607 (58,3%) T2, 76(7,3%) T3, 33 (3,2%) T4 in 9 (0,9%) TX. Pri 46,2% bolnic se je rak razširil v pazdušne bezgavke. Invazivni duktalni karcinom je bil histološko potrjen pri67,4% bolnic v skupini A in 84% v skupini B. Sistemsko smo zdravili 133 (56,4%) bolnic iz skupini A in 857 (76,4%) bolnic iz skupine B. (Izvleček skrajšan na 2000 znakov)</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:doc-TUKOANU7"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:doc-TUKOANU7" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:doc-TUKOANU7/02b7419a-ded5-4b07-96bb-85480e46ad81/PDF" /><edm:rights rdf:resource="http://creativecommons.org/licenses/by/4.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Društvo radiologije in onkologije</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:doc-TUKOANU7/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:doc-TUKOANU7" /></ore:Aggregation></rdf:RDF>